Jyothi Puram
Internal Medicine · Springfield, OHNPI 1699879189
Payments from drug & device makers
Across 72 payments — averaging $26.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$579
- AbbVie$306
- Novo Nordisk$110
- Novartis$96
- Merck$96
- Lilly USA, LLC$89
- plus $609 from 16 others
What the payments were for
- Food & beverage$1,884100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $579 |
| AbbVie(2 entities) | 6 | $306 |
| Novo Nordisk | 8 | $110 |
| Novartis | 3 | $96 |
| Merck | 6 | $96 |
| Lilly USA, LLC | 4 | $89 |
| Amgen | 7 | $88 |
| Pfizer | 5 | $79 |
| Boehringer Ingelheim | 4 | $76 |
| Akebia Therapeutics Inc | 1 | $75 |
| Johnson & Johnson | 2 | $58 |
| Alnylam Pharmaceuticals Inc. | 1 | $41 |
| Astellas Pharma US Inc | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| GSK | 2 | $23 |
| Abbott | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Merz North America, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,884 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 79 | $97,112 |
| OzempicSemaglutide | 67 | $95,242 |
| JardianceEmpagliflozin | 82 | $86,069 |
| TrulicityDulaglutide | 55 | $78,106 |
| EliquisApixaban | 45 | $56,293 |
| XareltoRivaroxaban | 26 | $24,670 |
| MyrbetriqMirabegron | 24 | $23,332 |
| EntrestoSacubitril/Valsartan | 12 | $15,793 |
| JanuviaSitagliptin Phosphate | 12 | $11,027 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 77 | $10,324 |
| Solifenacin Succinate | 77 | $6,140 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 204 | $5,642 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $4,087 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,644 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 19 | $3,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $579 | $97,11279 claims |
| Novo NordiskOzempic | $110 | $95,24267 claims |
| Boehringer IngelheimJardiance | $76 | $86,06982 claims |
| Lilly USA, LLCTrulicity | $89 | $78,10655 claims |
| PfizerEliquis | $79 | $56,29345 claims |
| Johnson & JohnsonXarelto | $58 | $24,67026 claims |
| Astellas Pharma US IncMyrbetriq | $30 | $23,33224 claims |
| NovartisEntresto | $96 | $15,79312 claims |
| MerckJanuvia | $96 | $11,02712 claims |
| GSKIncruse Ellipta | $23 | $3,64411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Springfield
- Narinder SainiSpringfield$3.2M
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.